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A modular approach toward producing 
nanotherapeutics targeting the innate immune system
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Marianne E. Burnett1, Emma D. Klein1, Anna Vera D. Verschuur1, Sheqouia A. Nauta1, 
Jazz Munitz1, Geoffrey Prévot1, Esther M. van Leeuwen1, Farideh Ordikhani4, Vera P. Mourits5, 
Claudia Calcagno1, Philip M. Robson1, George Soultanidis1, Thomas Reiner6,7,8, Rick R. M. Joosten9, 
Heiner Friedrich9,10, Joren C. Madsen11, Ewelina Kluza10,12, Roy van der Meel10,12, Leo A. B. Joosten5, 
Mihai G. Netea5,13, Jordi Ochando4, Zahi A. Fayad1, Carlos Pérez-Medina14,  
Willem J. M. Mulder1,10,12*, Abraham J. P. Teunissen1*
Immunotherapies controlling the adaptive immune system are firmly established, but regulating the innate 
immune system remains much less explored. The intrinsic interactions between nanoparticles and phagocytic 
myeloid cells make these materials especially suited for engaging the innate immune system. However, develop-
ing nanotherapeutics is an elaborate process. Here, we demonstrate a modular approach that facilitates efficient-
ly incorporating a broad variety of drugs in a nanobiologic platform. Using a microfluidic formulation strategy, we 
produced apolipoprotein A1–based nanobiologics with favorable innate immune system–engaging properties as 
evaluated by in vivo screening. Subsequently, rapamycin and three small-molecule inhibitors were derivatized 
with lipophilic promoieties, ensuring their seamless incorporation and efficient retention in nanobiologics. A short 
regimen of intravenously administered rapamycin-loaded nanobiologics (mTORi-NBs) significantly prolonged al-
lograft survival in a heart transplantation mouse model. Last, we studied mTORi-NB biodistribution in nonhuman 
primates by PET/MR imaging and evaluated its safety, paving the way for clinical translation.
INTRODUCTION
In the past decade, immunotherapy has emerged as a revolutionary 
cancer treatment. Clinically relevant immunotherapies, such as chi-
meric antigen receptor T cells and immune checkpoint inhibition, 
engage the adaptive immune system and mount a highly specific 
response (1). While the value of these therapeutic approaches is in-
disputable, targeting the innate immune system also holds great 
promise (1, 2) but remains largely unexplored.
The innate immune system provides nonspecific protection 
against invading pathogens through myeloid cells with diverse 
functions. In addition, myeloid cells, in particular, dendritic cells and 
macrophages, can invoke an antigen-specific adaptive immune response. 
Myeloid cells are activated by pathogen- or damage-associated mo-
lecular patterns through pattern recognizing receptors. Upon their 
activation, myeloid cells undergo metabolic and epigenetic rewir-
ing, leading to a hypersensitivity toward subsequent encounters 
with both related and unrelated pathogens. This phenomenon is 
termed “trained immunity” and can persist for several months (3).
Therapeutically managing trained immunity is a promising 
treatment paradigm for diseases characterized by excessive inflam-
mation, such as autoimmune disorders, cardiovascular disease, and 
allograft rejection (1, 2). This can be achieved by treating myeloid 
cells and their progenitors with drugs that modulate the metabolic 
or epigenetic programming underlying trained immunity. However, 
exploiting small-molecule inhibitors in this manner is hampered by 
the low myeloid cell specificity of these drugs.
Here, we report on a nanobiologic platform composed of apoli-
poprotein A1 (apoA-I)–based nanomaterials that efficiently target 
myeloid cells and their bone marrow progenitors. To enable nano-
biologics’ modular functionalization with small-molecule inhibi-
tors, we established a strategy in which these drugs are derivatized 
with biocleavable lipophilic promoieties (4). Using microfluidic 
formulation technology, we generated differently sized nanobiolog-
ics ranging from 20 to 120 nm. Their biodistribution and immune 
cell specificity were assessed by combining in vivo positron emis-
sion tomography (PET) imaging and ex vivo gamma counting with 
flow cytometry assays. On the basis of this screening, the 35-nm-
sized nanobiologic formulation was selected for further studies. To 
investigate the approach’s versatility, we loaded the 35-nm-sized 
nanobiologics with different small-molecule inhibitors, including the 
mammalian target of rapamycin (mTOR) inhibitor rapamycin, and 
found that our prodrug approach resulted in universal and highly 
efficient drug incorporation and retention. The immunotherapeu-
tic benefits of these drug-loaded nanobiologics were subsequently 
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assessed physicochemically and in vitro. On the basis of these find-
ings, we subjected the mTOR inhibiting nanobiologics (mTORi-NBs) 
to an optimization and in vivo evaluation process. In addition to 
experiments in a heart allograft transplantation mouse model, we 
studied mTORi-NBs’ biodistribution and toxicity profile in non- 
human primates.
RESULTS
Developing nanobiologics with high affinity 
for myeloid cells
Efficient nanotherapeutic modulation of the innate immune system 
requires a biocompatible nanocarrier with high affinity for innate 
immune cell–rich organs (i.e., the spleen and bone marrow). High- 
density lipoprotein (HDL) is a natural nanocarrier responsible for 
the transport of fat and other biomolecules (5). apoA-I is the major 
protein constituent of native HDL and interacts with scavenger 
receptors and the adenosine triphosphate (ATP)–binding cassette 
transporters ABCA1 and ABCG1, abundantly present on myeloid 
cells (6). On the basis of apoA-I, we developed innate immune 
cell–targeting nanocarriers, which we termed nanobiologics. We 
here present four differently sized nanobiologics composed of 
phospholipid 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), 
lysolipid 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine 
(PHPC), apoA-I, and cholesterol (Fig. 1A) (7–9). The triglyceride 
tricaprylin—chosen because of its high biocompatibility (10, 11)—
was incorporated in the three largest nanobiologics. The nanobio-
logics were produced by mixing a phosphate-buffered saline (PBS) 
solution of apoA-I with an acetonitrile solution containing POPC 
and PHPC lipids, cholesterol, and optional tricaprylin using a mi-
crofluidic chip setup. By controlling flow rates and the acetonitrile 
solution composition, nanobiologics with sizes of 20, 35, 65, and 
120  nm were obtained (dispersities typically below 0.2; fig. S1A). 
Using this easily scalable approach, a single person was able to for-
mulate up to 12 batches of nanobiologics per day.
Next, we studied the physicochemical properties of the nano-
biologics. We determined their stability when stored in PBS at 
4°C. Dynamic light scattering (DLS) measurements showed that the 
20-, 35-, and 65-nm formulations remained stable for at least 10 days, 
while the 120-nm formulation gradually reduced in size (Fig. 1B), 
which was accompanied by the appearance of a triglyceride phase 
on top of the nanobiologic emulsion. Therefore, we subsequently 
focused on the development and evaluation of the 20-, 35-, and 
65-nm-sized formulations. Cryogenic transmission electron micro-
scopy (cryo-TEM) analyses uncovered the 20-nm nanobiologic as 
circular shapes, which match the discoidal morphology we previ-
ously observed by TEM and cryo-TEM for similar formulations 
(7, 12). In contrast, the 35- and 65-nm nanobiologics have uniform 
contrast and a seemingly spherical shape as a result of their trica-
prylin core (Fig. 1C).
To determine pharmacokinetics and biodistribution in mice, 
nanobiologics were radiolabeled by functionalizing apoA-I with the 
chelator deferoxamine (DFO). The DFO-decorated nanobiologics 
were subsequently used to chelate the radioisotope 89Zr using a pro-
cedure we previously developed (13). The resulting 89Zr-radiolabeled 
nanobiologics were intravenously administered to C57BL/6 mice 
(n  =  7 for each formulation). At 24 hours after administration, 
in vivo PET/computed tomography (CT) imaging was performed 
(n = 2 per nanobiologic; Fig. 1D), while nanobiologic blood half-life 
and uptake in major organs was determined by ex  vivo gamma 
counting (n = 5 per nanobiologic; Fig. 1, E and F, fig. S1B, and table 
S1). We found a similar in vivo behavior for all three formulations, 
with the 20-nm nanobiologics circulating slightly longer than the 
35- and 65-nm nanobiologics (Fig. 1E and table S2). As expected, 
we found high nanobiologic uptake in the spleen and clearance or-
gans such as the liver and kidneys (14). Relative to the liver, we mea-
sured a significantly higher nanobiologic uptake in the bone marrow 
for the 35-nm formulation compared to the 65-nm variant. Although 
not statistically significant, a similar trend was observed for the 
spleen-to-liver and lymph node–to–liver ratios (Fig. 1F and fig. 
S1C). To analyze nanobiologic behavior on a cellular level, the high-
ly lipophilic dye DiOC18 (3) was incorporated and intravenously 
administered to C57BL/6 mice. Animals were sacrificed 24 hours 
later, and cellular uptake of DiOC18 (3) was assessed by flow cyto-
metric analyses of leukocytes in the bone marrow, blood, and 
spleen. All nanobiologics displayed a high affinity for myeloid cells 
as well as uptake in hematopoietic stem and progenitor cells (HSPCs), 
with negligible uptake by B and T lymphocytes (Fig. 1G and fig. S2, 
A and B). On the basis of its high bone marrow and Ly6Chi mono-
cyte uptake, we selected the 35-nm nanobiologic for ensuing studies.
Fluorescent model drug delivery to myeloid cells
The efficient exploitation of the 35-nm-sized nanobiologic as an 
immunotherapeutic requires high compatibility between its tri-
glyceride core and therapeutic payload. As physicochemical prop-
erties widely vary, we set out to develop a prodrug approach that 
enhances the therapeutic payload’s lipophilicity by functionalizing 
it with apolar promoieties. We first evaluated this approach’s 
potential using BODIPY carboxylic acid (BODIPY) as a model 
drug, allowing the in vivo evaluation of the 35-nm-sized nanobio-
logic by flow cytometric analyses. Lipophilic BODIPY derivatives 
were created by esterifying this compound with either an aliphatic 
C18 chain (BODIPY-aliphatic) or cholesterol (BODIPY-cholesterol; 
Fig. 2A and fig. S3). The aliphatic promoieties were chosen because 
these chains are the predominant constituents of both the nanobio-
logic triglyceride core and its phospholipid corona. As cholesterol 
stably incorporates in native lipoproteins, we also used this promoi-
ety to facilitate payload incorporation into nanobiologics (15). Both 
hydrolysable model prodrugs were successfully incorporated in the 
35-nm nanobiologics with recoveries of approximately 60%, while 
the recovery of unfunctionalized BODIPY was negligible (defined as 
100% * the amount of drug in the nanobiologics/the starting amount; 
Fig. 2, B and C, see table S3 for analytical methods). Dialyzing the 
nanobiologics against fetal bovine serum (FBS) at 37°C [10-kDa MWCO 
(molecular weight cut-off)] for 24 hours did not result in notable 
prodrug release or hydrolysis (Fig. 2D). Although these conditions 
do not fully mimic the in vivo environment, these results corroborate 
the nanotherapeutics’ stability. We next set out to examine nanobiologic 
delivery of BODIPY model prodrugs to HSPCs and myeloid cells in 
the bone marrow. Formulations containing 1×, 5×, or 25× a reference 
amount of either BODIPY-aliphatic or BODIPY-cholesterol (Fig. 2E) 
were intravenously administered to mice at a fixed nanobiologic dose, 
resulting in varying doses of BODIPY model prodrug (0.1, 0.5, and 
2.5 mg/kg). For nanobiologics loaded with BODIPY- aliphatic, 
flow cytometry analysis revealed a nearly linear relationship between 
the nanobiologic payload and the mean BODIPY fluorescence inten-
sity in bone marrow Ly6Chi monocytes. BODIPY-cholesterol– loaded 
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Fig. 1. Investigating the nanobiologics’ stability, biodistribution, and immune cell engagement. (A) Composition and morphology of the nanobiologics, formulated 
by microfluidic mixing. (B) Size and stability of the nanobiologics in PBS at 4°C, as measured by DLS. The mean of the number average size distribution is reported. While 
the 20-, 35-, and 65-nm formulations remained stable, the 120-nm variant shrunk over time and was therefore excluded from subsequent experiments; n = 3 for each 
nanobiologic size. (C) Representative cryo-TEM images of the 20-, 35-, and 65-nm-sized nanobiologics. Scale bar, 100 nm. (D to F) C57BL/6 mice were intravenously injected 
with 89Zr-labeled nanobiologics. (D) Representative maximum intensity projections of PET/CT scans performed 24 hours after injection. (E) Nanobiologics’ blood pharma-
cokinetics were fitted with a biexponential decay function; n = 5 per formulation. (F) Nanobiologic uptake in the femur’s bone marrow divided by nanobiologic uptake in 
the liver, measured at 24 hours after injection. (G) C57BL/6 mice were injected with DiOC18(3)-labeled nanobiologics, and DiOC18(3) uptake was measured 24 hours 
after injection in various bone marrow cell populations by flow cytometry. Gating strategy and average mean fluorescence intensity (MFI) values are shown; n = 4 per 
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no increase in fluorescence signal was observed after administering 
identical doses of bare BODIPY (Fig. 2, F and G). The differences in 
mean fluorescence intensity (MFI) between the two types of model 
prodrugs likely stem from differences in their distribution within 
the nanocarrier (4, 16). These results show that our combined nano-
biologic and lipophilic prodrug approach can be used to efficiently 
deliver drugs to myeloid (progenitor) cells in the bone marrow.
Establishing and screening nanobiologics loaded 
with different drugs
After developing an effective drug loading strategy for nanobiologics, 
we set out to investigate the approach’s versatility. For this purpose, 
we selected four (small molecule) drugs based on their ability to 
inhibit trained immunity by targeting specific metabolic or epigen-
etic processes. These drugs vary greatly in function, size, and physico-
chemical properties (Fig. 3A). Diethyl malonate is a low–molecular 
weight and highly water-soluble prodrug for malonic acid, which re-
duces mitochondrial reactive oxygen species production by inhibit-
ing succinate oxidation and thereby reduces inflammation (17). 
(+)-JQ1 is a moderately sized and relatively rigid drug that targets 
bromodomains (18). It suppresses inflammation, atherogenesis, 
and various forms of cancers in mice, but it is currently not used in 
humans because of its short biological half-life. GSK-J4 is a moder-
ately sized and more flexible compound that inhibits H3K27me3 
demethylases, thereby reducing macrophages’ proinflammatory re-
sponse to lipopolysaccharide (LPS) stimulation (19). Although this 
drug’s active form consists of the carboxylic acid form (GSK-J1), the 
ethyl ester prodrug (GSK-J4) is used to achieve efficient cell pene-
tration (19). Last, rapamycin is a relatively large drug that inhibits 
the mTOR pathway, which plays a central role in trained immunity 
regulation (20).
Using the same lipophilic prodrug strategy as used for the 
BODIPY model prodrugs, we functionalized malonate, rapamycin, 
(+)-JQ1, and GSK with either cholesterol or a C18 aliphatic chain 
(fig. S4). While malonate, (+)-JQ1, and GSK analogs were synthe-
sized using straightforward esterification chemistry, the derivatiza-
tion of rapamycin is more challenging. Rapamycin’s three alcohol 
moieties complicate mono-esterification, which is necessary to minimize 
hydrolysis of its macrocyclic ester before in vivo generation of the 
parent drug. Fortunately, site-specific functionalization of only one 
of rapamycin’s alcohols (the 42-OH position, on the cyclohexyl 
moiety) was achieved by enzymatic esterification using Novozyme 
435, yielding rapamycin-aliphatic (21). A similar procedure proved 
ineffective at functionalizing rapamycin with cholesteryl hemisuc-
cinate, presumably due to steric hindrance.
The anti-inflammatory properties of the seven resulting lipo-
philic prodrugs were investigated in vitro by assessing their ability 
to reduce cytokine production upon LPS stimulation. Bone marrow 
cells from C57BL/6 mice were incubated with prodrugs and stimu-
lated with LPS. The malonate prodrugs proved insoluble at thera-
peutic concentrations and were therefore not analyzed. Of the five 
remaining prodrugs, all except (+)-JQ1-aliphatic reduced tumor 
necrosis factor– (TNF) production upon LPS stimulation when 
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Fig. 2. Assessing the nanobiologics’ ability to deliver drugs to the bone marrow. (A) Molecular structure of the fluorescent model drug BODIPY FL carboxylic acid as 
well as aliphatic and cholesterol functionalized derivatives. (B) Size of nanobiologics loaded with BODIPY or its derivatives as measured by DLS. The mean of the number 
average size distribution is displayed; n = 3. (C) Recovery of BODIPY and its derivatives as measured by high-performance liquid chromatography (HPLC), defined as the 
amount of (pro)drug in the nanobiologics divided by the amount used for their formulation; n = 2. (D) Release rate of the BODIPY derivatives from the nanobiologics when 
dialyzed against FBS at 37°C (10-kDa MWCO), as measured by HPLC. Data points are fitted with a biexponential decay function; n = 2. (E to G) Nanobiologics were formu-
lated containing increasing amounts of either BODIPY-aliphatic or BODIPY-cholesterol. C57BL/6 mice were injected with identical doses of nanobiologics, leading to the 
administration of varying amounts of BODIPY model prodrugs; e.g., nanobiologics loaded with 5× more fluorophore were injected at a 5× higher fluorophore dose. 
Twenty-four hours after injection, MFI of Ly6Chi monocytes was measured by flow cytometry. (E) Schematic overview of the experimental design. (F) Representative his-
tograms of BODIPY signal in bone marrow Ly6Chi monocytes from mice injected with increasing doses of BODIPY-cholesterol, but the same amount of nanobiologic. (G) 
MFI of the bone marrow’s Ly6Chi monocytes after administering nanobiologics loaded with various amounts of BODIPY-aliphatic or BODIPY-cholesterol; n = 4. Lines are 
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After synthesizing and evaluating the different (pro)drugs, we 
formulated these compounds in our 35-nm nanobiologic platform, 
using a 6.5 weight % (wt %) (pro)drug to triglyceride ratio. All for-
mulations were similar in size and dispersity (Fig. 3C and fig. S5B). 
Furthermore, our prodrug approach resulted in greatly improved 
incorporation efficiencies compared to the parent drugs, with the 
recovery of all parent drugs below 20% and all prodrugs above 80%. 
(Fig. 3D). Unexpectedly, no significant differences were observed 
between cholesterol and aliphatically functionalized derivatives of 
the same parent drug. No hydrolytic cleavage of the promoieties 
was observed over 10 days upon storing the nanobiologics in PBS at 
4°C. While some hydrolysis of rapamycin-aliphatic’s macrocyclic 
ester was observed, this was limited to approximately 1.0% per day 
(fig. S5C). Hydrolysis of unfunctionalized rapamycin in the nano-
biologic solution was notably faster but could not be accurately 
quantified. Together, our results show that, by forming lipophilic 
prodrugs, a broad variety of therapeutic compounds can be stably 
incorporated in the 35-nm nanobiologic platform.
Optimizing drug payload of an mTOR-targeting 
nanobiologic
For the remainder of the study, we focused on rapamycin-aliphatic 
nanobiologics as the mTOR pathway is a key regulator of innate 
immune cell function. We first optimized the loading of our 
rapamycin- aliphatic prodrug (Fig. 4A). We were able to increase the 
rapamycin- aliphatic payload by a factor 3 without affecting prodrug 
incorporation efficiency or nanobiologic size and stability (Fig. 4, B 
and C, see fig. S6 for cryo-TEM image of mTORi-NBs). Further 
increasing the amount of rapamycin-aliphatic resulted in turbid 
solutions and increased nanobiologic sizes. We will refer to the 
mTOR-targeting nanobiologic formulated using 19.5 wt % rapamycin- 





































































































































































































































































Fig. 3. Establishing a library of nanotherapeutics. (A) All drugs were functionalized with either an aliphatic chain or cholesterol using a hydrolyzable ester linkage, 
except for rapamycin, of which only the aliphatic derivative was synthesized. (B) Murine bone marrow cells were incubated with (pro)drugs and stimulated with lipopoly-
saccharide (LPS; 100 ng/ml) for 24 hours. Subsequently, tumor necrosis factor– (TNF) production was measured by enzyme-linked immunosorbent assay; n = 3 to 4. 
(C) Size of the nanobiologics as measured by DLS, showing that the type of (pro)drug incorporated has no notable effect on nanobiologic size. The mean of the number 
average size distribution is displayed; n = 3. (D) Recoveries of the various (pro)drugs in the nanobiologics as measured by HPLC, defined as the amount of (pro)drug in the 









acional de Investigaciones C
ardiovasculares on Septem
ber 28, 2021
van Leent et al., Sci. Adv. 2021; 7 : eabe7853     5 March 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 12
loading experiments using GSK-aliphatic or (+)-JQ1-cholesterol 
yielded similar results, indicating that a prodrug to triglyceride 
mass ratio of ~1 to 5 represents an optimum for this nanobiologic 
platform (fig. S7). To assess their ability to induce immunological 
tolerance in vivo, we intravenously administered mTORi-NBs to 
C57BL/6 mice on days 0, 2, and 5 at an equivalent dose of 1.0 or 
5.0 mg of rapamycin per kilogram (Fig. 4D). Bone marrow cells 
were harvested on day 6 and stimulated with LPS in vitro. Cells 
from mice treated with mTORi-NBs at 5.0 mg/kg displayed a less 
inflammatory phenotype, as indicated by a reduction in TNF and 
interleukin-6 (IL-6) production following LPS stimulation, com-
pared to PBS-treated animals (Fig.  4,  E  and  F). No signs of liver 
toxicity were observed at this dose (Fig. 4G).
mTOR-targeted nanobiologic immunotherapy prolongs 
heart allograft survival
We have previously reported a myeloid cell–specific nanotherapy 
and demonstrated its ability to induce allograft tolerance in a mouse 
allogeneic heart transplantation model (2). Specifically, this treatment 
reduces glycolysis in macrophages and diminishes the epi genetic 
modifications underlying inflammatory cytokine production. In 
turn, these macrophages promote CD4+ regulatory T cell expansion 
at the expense of alloreactive CD8+ T cell–mediated immunity.
Inspired by these results, we evaluated mTORi-NB immuno-
therapy’s efficacy in the same heart transplantation model. First, we 
radiolabeled mTORi-NBs with 89Zr to study their biodistribution by 
PET imaging in mice that underwent heart allograft transplantation. 
Our results reveal high bone marrow uptake and comparable accu-
mulation between the endogenous and allograft hearts (Fig. 4, H and I). 
We also evaluated mTORi-NB immunotherapy’s ability to prolong 
allograft survival. Mice were treated with either mTORi-NBs (5.0 mg/kg), 
nanobiologics containing no drug, or PBS, directly before as well as 
2 and 5 days after transplantation. All mice treated with PBS or un-
loaded nanobiologics had rejected their transplants by day 10, while 
the allografts of all mTORi-NB–treated animals were still viable 
15 days after transplantation (Fig. 4J). Eight weeks after transplan-
tation, 62.5% of the mTORi-NB–treated mice had not rejected the heart 
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Fig. 4. Using mTORi-nanobiologics to prevent organ rejection in a mouse heart allograft model. (A to C) Nanobiologics were formulated using 1×, 3×, and 5× a 
reference amount of rapamycin-aliphatic (equaling prodrug/triglyceride wt % of 6.50, 19.5, and 32.5, respectively), schematically shown in (A). (B) Amount of rapamycin- 
aliphatic recovered and (C) size of the nanobiologics when formulated using the various amounts of rapamycin-aliphatic; n = 3 for each composition. The formulation 
containing 3× our reference amount of rapamycin-aliphatic (containing ~20 wt % prodrug compared to triglycerides) was chosen as lead candidate and highlighted with 
a gray bar. This formulation was termed mTORi-NB. (D to G) C57BL/6 mice were treated with three intravenous injections of either mTORi-NBs at 1.0 or 5.0 mg/kg, a cor-
responding dose of unloaded nanobiologics, or PBS. Bone marrow cells were harvested on day 6 and stimulated with LPS, schematically shown in (D). (E) TNF and (F) IL-6 
production upon in vitro LPS stimulation; n = 4 to 6. (G) Alanine aminotransferase (ALT) blood levels in U/liter; n = 10 to 12. (H to J) C57BL/6 mice received an allogenic 
heart transplant. (H) Representative maximum intensity projection of a PET/CT scan and (I) organ-specific uptake at 24 hours after 89Zr-labeled mTORi-NB injection. (J) 
Allograft survival in mice treated with mTORi-NBs, the unloaded 35-nm nanobiologics, or PBS, directly before as well as 2 and 5 days after transplantation. Data are rep-
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mTOR-targeted nanobiologic immunotherapy is safe 
in nonhuman primates
To facilitate clinical translation of our nanobiologic platform, we 
studied mTORi-NB biodistribution and toxicity in two nonhuman 
primates. 89Zr-labeled mTORi-NBs were intravenously adminis-
tered, and their in vivo distribution was examined using a fully 
integrated three-dimensional (3D) PET/magnetic resonance imag-
ing (MRI) protocol that we developed previously (14). The PET/
MRI protocol allows acquiring high-quality and high-resolution ana-
tomical information while simultaneously detecting 89Zr-labeled 
nanobiologics by PET imaging with high sensitivity and accuracy. 
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Fig. 5. Biodistribution and safety of mTORi-nanobiologics in nonhuman primates. Two nonhuman primates weighing 5.99 and 10.13 kg were injected with 89Zr-labeled 
mTORi-NB. (A) Representative 3D-rendered images acquired in the first hour after injection using dynamic PET/MR. (B) Quantification of 89Zr-labeled mTORi-NB PET signal 
in liver, spleen, kidneys, and bone marrow. (C) Representative whole-body PET/MR images, 2 and 48 hours after injection of 89Zr-labeled mTORi-NBs. (D) PET-based quan-
tification of 89Zr-labeled mTORi-NB uptake in various organs at 48 hours after injection. (E) Blood pharmacokinetics measured by ex vivo gamma counting of blood 
samples, as well as the associated weighted blood half-life obtained by fitting the data with a biexponential decay function. (F) Aspartate aminotransferase (AST), creati-
nine, and blood urea nitrogen (BUN) levels before (Pre) and 48 hours after (Post) injection. White areas represent normal ranges for male cynomolgus monkeys (35). For 









acional de Investigaciones C
ardiovasculares on Septem
ber 28, 2021
van Leent et al., Sci. Adv. 2021; 7 : eabe7853     5 March 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
8 of 12
administration, mTORi-NBs accumulated in the spleen, liver, kid-
ney, and bone marrow (Fig. 5, A and B). Static whole-body PET/
MRI was performed 2 and 48 hours after injection, allowing quan-
tification of nanobiologic distribution. At 48 hours after injection, 
we found the mTORi-NBs mainly accumulated in the liver, spleen, 
kidney, and bone marrow, while we observed very little activity in 
the heart, lungs, and brain (Fig. 5, C and D). The weighted blood 
half-life of a single mTORi-NB dose was 59.8 min, as determined by 
ex vivo gamma counting of blood samples (Fig. 5E and table S4). 
Blood chemistry analyses showed no signs of liver or kidney dam-
age 48 hours after injection (Fig. 5F). These results indicate that the 
in vivo behavior and biocompatibility of mTORi-NBs are preserved 
across species.
DISCUSSION
In this study, we present a modular approach for producing nano-
therapeutics that efficiently engage the innate immune system. 
These nanotherapeutics are based on highly biocompatible nanobi-
ologics that are formulated from natural molecular building blocks, 
namely, phospholipids, other fatty molecules, and apoA-I, using a 
simple, fast, and reproducible microfluidic formulation process 
(22). In mouse studies, we found that the 35-nm-sized nanobiologics 
rapidly accumulate in hematopoietic organs and display a strong 
affinity for myeloid cells and their progenitors.
Our prodrug strategy allows efficient and stable nanobiologic 
loading with a broad variety of drugs. All prodrugs were incorporated 
with similar efficiencies without affecting nanobiologic size or dis-
persity. In other words, instead of pursuing conventional drug formu-
lation strategies focused on modifying the nanocarrier, we chemically 
modified the therapeutic payload to be inherently compatible with 
our optimized nanobiologic platform. Therefore, our combined nano-
biologic and prodrug approach allows producing nanotherapeutics 
for targeting myeloid (progenitor) cells in a modular, yet highly re-
producible fashion.
After showing that a variety of drugs can be straightforwardly 
incorporated in our nanobiologic platform, we demonstrated its 
high propensity for myeloid cell uptake. We optimized the load-
ing of a rapamycin prodrug in nanobiologics to yield mTORi-NBs. 
mTORi-NBs therapy significantly promoted organ transplant ac-
ceptance in a murine model of heart allograft transplantation 
without the need for chronic immunosuppression. In mice treated 
with mTORi-NBs, more than half of the allografts survived over 60 
days, whereas all allografts in animals treated with PBS or unloaded 
nanobiologics rejected within 10 days after transplantation. We ob-
served a similar biodistribution of mTORi-NBs in nonhuman pri-
mates as observed in mice, with no signs of toxicity in either species. 
These results show that nanobiologics’ favorable in vivo features are 
preserved across species. Nanobiologics enhance the bioavailability 
for innate immune cells, which is concurrently expected to reduce 
systemic side effects. In the case of rapamycin, insulin resistance 
and impaired wound healing are avoided (23, 24).
In future research, we will focus on expanding our prodrug library 
with additional therapeutic agents as well as different promoi-
eties and biocleavable groups. The relation between promoiety 
structure and prodrug in vivo behavior will be of special interest. 
Although our current study used drugs that induce immunological 
tolerance, similar platforms can be used to initiate other types of 
innate immune responses (12). Producing these immunostimulatory 
nanotherapeutics in a modular fashion could greatly benefit treat-
ing a broad variety of diseases, including cancer or coronavirus dis-
ease 2019 (COVID-19) (25, 26). We expect our modular approach 
to greatly benefit from current developments in high-throughput 
screening and machine learning, further accelerating nanothera-
peutic development and clinical translation (27, 28). Clinical trans-
lation is further facilitated by the ease with which our microfluidic 
nanobiologic formulation technology can be scaled up (22). apoA-I 
has been produced (in sufficient amounts) for safe application in 
humans (29–32).
In summary, we developed a robust and fully modular approach 
toward producing nanotherapeutics with a high propensity to accu-
mulate in hematopoietic organs where they target myeloid cells. 
The latter facilitates efficient modulation of the innate immune re-
sponse, which we demonstrated in vitro and in vivo in a heart 
allograft mouse model. Through easily scalable production and safe 
application in nonhuman primate models, we have demonstrated 
the clinical translatability of our nanobiologic platform.
MATERIALS AND METHODS
Materials
All chemicals were purchased from Sigma-Aldrich, Medchem Express, 
or Selleckchem, except p-SCN-Bn-Defereoxamine that was obtained 
from macrocyclics. PES (polyethersulfone) syringe filters were obtained 
from CELLTREAT. A BS-8000 model microfluidic pump from Braintree 
Scientific Inc. was used to formulate the nanobiologics in combina-
tion with Zeonor herringbone mixers from microfluidic ChipShop 
(product code: 10000076). Particles were purified using a 100-kDa 
MWCO 20-ml Vivaspin centrifugal filter. Dialysis bags were from 
Thermo Fisher Scientific (product no. 66383). The apoA-1 protein 
was purified in house using a combination of ultracentrifugation 
and precipitation in chloroform/methanol. DLS and zeta potential 
measurements were performed on a Brookhaven Instruments Cor-
poration ZetaPALS analyzer. 1H and 13C nuclear MR samples were 
analyzed using a Bruker 600 ultrashield magnet connected to a 
Bruker advance 600 console, and data were processed using TopSpin 
version 3.5 pl 7. Quantitative analysis of all drugs, except diethyl 
malonate and its derivatives, was performed by high-performance 
liquid chromatography (HPLC) using a Shimadzu UFLC apparatus 
equipped with either a C18 or CN column. Acetonitrile and water 
(each with 0.1% trifluoroacetic acid) were used as mobile phase, and 
compounds were detected with an SPD-M20a diode array detector. 
Diethyl malonate was analyzed using an Agilent Technologies 
5977B MSD 7890B gas chromatography–mass spectrometry (GC-MS), 
equipped with an HP5MS 30-m, 0.25-mm, 0.25-m column. Ali-
phatic and cholesterol-derivatized malonate were analyzed with a 
Waters ACQUITY UPC2 SFC (supercritical fluid)–MS using an 
isopropanol/water mixture as a mobile phase and a 1-aminoantracene 
column. Radiolabeling of the nanoparticles was performed using a 
procedure previously reported by us (13, 22). Elemental analysis 
was outsourced to Galbraith Laboratories.
Formulating the 35-nm nanobiologics
From stock solutions (10 mg/ml) in chloroform, POPC (250 l), 
PHPC (65 l), cholesterol (15 l), tricaprylin (1000 l), and optional 
(pro)drug (65 l) were combined in a 20-ml vial and dried under 
vacuum. The resulting film was redissolved in an acetonitrile/methanol 
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protein in PBS (24 ml, 0.1 mg/ml) was prepared. Using a micro-
fluidic setup, both solutions were simultaneously injected into a 
herringbone mixer, with a flow rate of 0.75 ml/min for the lipid 
solution and a rate of 6 ml/min for the apoA-I solution. The ob-
tained solution was concentrated by centrifugal filtration using a 
100 MWCO Vivaspin tube at 4000 rpm to obtain a volume of 5 ml. 
PBS (5 ml) was added and the solution was concentrated to 5 ml; 
this was repeated twice. The washed solution was concentrated to 
approximately 3 ml and filtered through a 0.22-m PES syringe 
filter to obtain the finished nanobiologics. To obtain nanobiologics 
for fluorescence-activated cell sorting (FACS) measurements, 3,3′- 
dioactadecyloxacarbocyanine perchlorate [DIOC18(3); 0.25 mg] was 
added to the acetonitrile solution.
Radiolabeling the nanobiologics
To obtain nanobiologics for 89Zr labeling, the nanobiologic solu-
tions were adjusted to pH 8 using a carbonate buffer and p-SCN-Bn- 
DFO (2 eq. per apoA-I) was added as a concentrated solution in 
dimethyl sulfoxide (no more than 5 volume %). The mixture was 
incubated at 37°C for 2 hours, and the solution was washed three 
times with water in a 100-kDa Vivaspin tube. A solution of 89Zr 
oxalate (1 M aqueous oxalic acid) was neutralized using sodium 
carbonate (1  M in water) until a pH between 6.8 and 7.4 was 
reached. The 89Zr solution was added to the DFO-containing nano-
biologics and incubated at 37°C using a thermomixer (600 rpm) for 
30 to 60 min. The resulting solution was purified by washing three 
times with water in a 10-kDa Vivaspin tube. The radiolabeled nano-
biologics’ radiochemical purity was typically over 95%, as assessed 
by size exclusion chromatography radio-HPLC.
Determination of nanobiologic size and dispersity by DLS
An aliquot (10 l) of the final nanobiologic solution was dissolved 
in PBS (1 ml), filtered through a 0.22-m PES syringe filter, and 
analyzed by DLS. Values are reported as the mean of the number 
average size distribution.
Determining drug recovery and hydrolysis
(Pro)drug recovery and hydrolysis were determined by drying an 
aliquot (200 l) of the nanobiologics under vacuum and dissolving 
the residue in acetonitrile (600 l) by sonicating for 5 min. The sus-
pension was centrifuged to precipitate any solids, and the remain-
ing solution was analyzed by HPLC using a PDA (photodiode array) 
detector, except for nanobiologics containing diethylmalonate, which 
were analyzed by GC-MS, and those containing malonate prodrugs, 
which were analyzed using SFC-MS.
Determining model drug release by dialysis in FBS
To compare the stability of the nanobiologics under in vivo–like 
conditions, the nanoparticles were dialyzed against FBS at 37°C. The 
nanobiologic solution (0.5 ml) was placed in a 10-kDa MWCO 
dialysis bag and suspended in FBS (45 ml) at 37°C. At predeter-
mined time points (0, 15, 30, 60, 120, and 360 min after starting the 
experiment), an aliquot (50 l) was taken from the dialysis bag and 
analyzed by HPLC as explained above. Experiments were per-
formed in duplicate using the same batch of nanobiologics. The ob-
tained kinetic data were fitted using a biexponential decay after 
testing for outliers (none were identified by Prism’s ROUT method 
using Q = 1%) and subsequently normalized using the y-axis inter-
cept of the fit.
Cryogenic transmission electron microscopy
Vitrified thin films for cryo-TEM analysis were prepared using an 
automated vitrification robot (FEI Vitrobot Mark IV) by plunge vit-
rification in liquid ethane. Before vitrification, a 200-mesh copper 
grid covered with a Quantifoil R 2/2 holey carbon film (Quantifoil 
Micro Tools GmbH) was surface plasma–treated for 40 s using a 
Cressington 208 carbon coater. Cryo-TEM imaging was carried out 
on the cryoTITAN (Thermo Fisher Scientific, previously FEI), 
equipped with a field emission gun, a post-column Gatan imaging 
filter (model 2002), and a post-GIF 2k × 2k Gatan charge-coupled 
device camera (model 794). The microscope was operated at 300-kV 
acceleration voltage in bright-field TEM mode with zero-loss energy 
filtering at a nominal magnification of ×24,000 and a dose rate of 
11.8 e−/Å2·s with a 1-s image acquisition time.
Animal models
Female C57BL/6 and BALB/c mice were purchased from The Jackson 
Laboratory. For nonhuman primate studies, two male cynomolgus 
monkeys (Macaca fascicularis) were used. All animals were cohoused 
in climate-controlled conditions with 12-hour light-dark cycles and 
provided water ad libitum. Mice were fed a standard chow diet. 
Nonhuman primates were fed Teklad Global 20% Protein Primate 
Diet. Animal care and experimental procedures were based on ap-
proved institutional protocols from the Icahn School of Medicine at 
Mount Sinai.
Pharmacokinetics in mice and nonhuman primates
To determine the in vivo half-life of the nanobiologics, 89Zr-labeled 
nanobiologics (106.4 ± 30.28 Ci) were intravenously injected in 
C57BL/6 mice. Blood was drawn at 1, 5, 15, and 30 min and 1, 2, 6, 
12, and 24 hours after injection. Two nonhuman primates weighing 
10.13 and 5.99 kg were injected with 2249 Ci and 1274 Ci 89Zr-labeled 
mTORi-NBs, respectively. Blood was drawn at 5, 30, and 90 min and 
48 hours after injection. Blood samples were weighed and gamma- 
counted using a Wizard2 2480 automatic gamma counter (PerkinElmer, 
Waltham, MA). Values were corrected for radioactive decay and ex-
pressed as a percentage of injected dose per gram of blood (%ID/g). 
Mouse and nonhuman primate data were fitted with a biexponential 
decay function. Weighted half-life was defined as follows: (% fast × 
t1/2 fast + % slow × t1/2 slow)/100.
Biodistribution studies
C57BL/6 mice were sacrificed 24 hours after injection of 89Zr- 
labeled nanobiologics and perfused with PBS (20 ml). Tissues of 
interest were harvested, weighed, and gamma-counted using a Wizard2 
2480 automatic gamma counter (PerkinElmer, Waltham, MA). Values 
were corrected for decay and expressed as a percentage of injected 
dose per gram of tissue (%ID/g).
PET/CT imaging of nanobiologic biodistribution in mice
89Zr-labeled nanobiologics (106.4 ± 30.28 Ci) were intravenously 
injected in C57BL/6 mice. Twenty-four hours later, mice were anes-
thetized using 1.0% isoflurane in O2 at a flow rate of ∼1.0 liter/min. 
PET/CT scans were performed using a Mediso nanoScan PET/CT 
(Mediso, Budapest, Hungary). A whole-body CT scan was per-
formed (energy, 50 kVp; current, 180 As; isotropic voxel size, 0.25 mm) 
followed by a 20-min PET scan. Reconstruction was performed 
with attenuation correction using the TeraTomo 3D reconstruction 
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were filtered with an energy window between 400 and 600 keV. The 
voxel size was isotropic with 0.4-mm width, and the reconstruction 
was applied for four full iterations, six subsets per iteration.
Determining cellular uptake of DiOC18-labeled or BODIPY 
model drug-loaded nanobiologics by flow cytometry
To study cellular specificity, C57BL/6 mice were injected with na-
nobiologics containing highly lipophilic DiOC18, dosed at 0.6 mg of 
DiOC18 per kilogram of mice. Similarly, (pro)drugs’ bone marrow 
delivery was qualitatively investigated by injecting mice with either 
bare BODIPY FL carboxylic acid, or nanobiologics loaded with 
aliphatic or cholesteryl ester derivatives thereof. Specifically, bare 
BODIPY FL carboxylic acid was injected at 0.1, 0.5, and 2.5 mg/kg. 
In addition, separate groups of animals were injected with constant 
amounts of nanobiologics, loaded with differing amounts of BODIPY 
prodrug. Nanobiologics containing 0.65, 3.25, or 16.25 wt % BODIPY 
(model prodrug) compared to tricaprylin (see table S2) were injected 
at 0.1, 0.5, and 2.5 mg/kg, respectively. Animals were euthanized 
24 hours later, and their blood was collected through cardiac punc-
ture. Blood samples were stored in EDTA-coated tubes. The ani-
mals were subsequently perfused with cold PBS (20 ml). Femurs 
and spleen were collected and stored in PBS. Bone marrow cells 
were flushed out of femurs and strained through a 70-m strainer. 
Spleens were fragmented and meshed through a 70-m strainer. 
Blood, bone marrow, and spleen samples were incubated with lysis 
buffer and washed with FACS buffer (Dulbecco’s PBS comple-
mented with 1% FBS, 1 mM EDTA, 0.5% bovine serum albumin, 
and 0.1% NaN3).
Single-cell suspensions were incubated with anti-CD115 (clone 
AFS98), anti-Ly6C (clone Al-21), anti-Ly6G (clone 1A8), anti-CD11b 
(clone M1/70), anti-CD19 (clone 1D3), and anti-CD90.2 (clone 
53-2.1). To determine uptake in stem and progenitor cells, bone 
marrow cells were stained with anti-CD48 (clone HM48-1), anti-CD150 
(clone TC15-12F12.2), anti-CD135 (clone A2F10), anti-CD117 (c-Kit) 
(clone 2B8), anti–Sca-1 (Ly6-A/E) (clone E13-161.7), anti-CD16/32 
(clone 93), anti-CD34 (clone RAM34), and a lineage cocktail con-
taining anti-CD3 (clone 500A2), anti-CD11b (clone M1/70), anti- 
CD45R/B220 (clone RA3-6B2), anti–Ly-76 (clone TER-119), and 
anti-Ly6G/Ly6C (clone RB6-8C5). Antibodies were purchased from 
BioLegend, BD Biosciences, and eBioscience. Data were acquired 
on a BD LSRFortessa (BD Biosciences). DiOC18 and BODIPY sig-
nals were detected in the fluorescein isothiocyanate (FITC) chan-
nel. Data were analyzed using FlowJo v10.4.0 (Tree Star).
In vivo nanobiologic treatment
Mice were treated directly before as well as 2 and 5 days after trans-
plantation with mTORi-NBs (5.0 mg/kg), an equivalent dose of un-
loaded nanobiologics, or PBS through lateral tail vein injection. 
mTORi-NBs were dosed at 1- or 5-mg effective amount of rapamy-
cin per kilogram of animal. Nonhuman primates were treated once 
with mTORi-NBs, intravenously, at 0.15 mg/kg. This is the equiva-
lent of the 1.0 mg/kg dose in mice, corrected for body surface 
area (33).
Assessing in vitro (pro)drug efficacy
Bone marrow cells were harvested from tibias and femurs of naïve 
C57BL/6 mice or C57BL/6 mice treated with nanobiologics. Cells 
were filtered through a 70-m strainer, incubated with lysis buffer, 
and washed with cold PBS. Cells were resuspended in complete 
medium (RPMI 1640 medium supplemented with 10% FBS and 1% 
penicillin-streptomycin, 1% l-glutamine solution, 1% minimum 
essential medium nonessential amino acids, and 1% Hepes buffer) 
at 0.75 × 106 cells/ml. Cells were seeded at 750,000 cells per well in a 
24-well plate. Cells of naïve mice were incubated with (pro)drugs 
and left to adhere for 1 hour (GSK and rapamycin) or 24 hours [(+)-
JQ1] at 37°C. We tested malonate at a concentration of 2.5 mM, 
(+)-JQ1 and its prodrugs at 50 nM, GSK and its prodrugs at 10 M, 
and rapamycin and its prodrug at 40 nM. Cells were stimulated 
with LPS at a concentration of 100 ng/ml for another 24 hours. Cells 
of mice treated with nanobiologics were left to adhere for 1 hour at 
37°C. Cells were stimulated with LPS at a concentration of 100 ng/ml 
for another 24 hours. The supernatant was collected and stored 
at −80°C until further analysis.
Quantification of cytokines in the cell culture supernatant
Cytokine production was determined in supernatants using com-
mercial enzyme-linked immunosorbent assay kits for murine TNF 
and IL-6 (Invitrogen) following the instructions of the manufacturer.
Cell viability assay
Bone marrow cells were harvested as described above and plated at 
50,000 cells per well in a 96-well plate. Cells were incubated with 
(pro)drugs for 24 hours. We tested malonate at a concentration of 
2.5 mM, (+)-JQ1 and its prodrugs at 50 nM, GSK and its prodrugs at 
10 M, and rapamycin and its prodrug at 40 nM. The CellTiter-Glo 
Luminescent Cell Viability Assay (Promega) was performed follow-
ing the instructions of the manufacturer.
Murine heart transplantation and allograft monitoring
Hearts of BALB/c mice were transplanted as fully vascularized het-
erotopic grafts into C57BL/6 mice as previously described (34). 
Briefly, hearts were transplanted into the peritoneal cavities of the 
recipients by establishing an end-to-side anastomosis between the 
donor and recipient aortae and end-to-side anastomosis between 
the donor pulmonary trunk and the recipient inferior vena cava. To 
determine cardiac allograft survival, transplanted hearts were checked 
two to three times per week by ultrasound. Hearts were imaged us-
ing a Vevo 2100 Imaging System (FUJIFILM VisualSonics Inc.) 
with an MS-400 transducer (30 MHz) in B-mode. Rejection was de-
fined as the complete absence of cardiac contraction. Graft survival 
among groups was plotted using Kaplan-Meier survival curves. Sta-
tistical significance was calculated using log-rank tests.
In vivo PET/MRI of nonhuman primates
PET and MR images were acquired on a combined 3T PET/MRI 
system (Biograph mMR, Siemens Healthineers). After an overnight 
fast, animals were anesthetized with ketamine (5.0 mg/kg) and dex-
medetomidine (0.0075 to 0.015 mg/kg), and blood was collected 
from the femoral vein. The animals were injected with 89Zr-labeled 
mTORi-NBs. Dynamic PET imaging was performed during the 
first 60 min after infusion, while static whole-body PET scans were 
performed starting at 1 and 48 hours after injection. During imaging, 
blood was collected at 5, 30, and 90 min, and 48 hours after injec-
tion, to determine the nanobiologics’ pharmacokinetics.
The dynamic PET bed was positioned to capture the kidneys, 
liver, spleen, and lumbar vertebrae. Static whole-body PET images 
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During dynamic imaging, MR parameters were as follows: ac-
quisition plane, coronal; repetition time, 1000 ms; echo time, 79 ms; 
number of slices, 144; number of averages, 4; spatial resolution, 
0.5 mm × 0.5 mm × 1.0 mm; and acquisition duration, 42 min and 
42 s. For whole-body imaging starting at 1 hour after injection, MR 
parameters were as follows: acquisition plane, coronal; repetition 
time, 1000 ms; echo time, 79 ms; number of slices, 160; number of 
averages, 1.4; spatial resolution, 0.6 mm × 0.6 mm × 1.0 mm; and 
acquisition duration, 14 min and 56 s per bed. For whole-body im-
aging starting at 48 hours after injection, MR parameters were as 
follows: acquisition plane, coronal; repetition time, 1000 ms; echo 
time, 79 ms; number of slices, 224; number of averages, 2; spatial 
resolution of 0.6 mm × 0.6 mm × 1.0 mm; acquisition duration, 
29 min and 56 s per bed.
Whole-body MR images from each bed were automatically col-
lated together with a scanner. After acquisition, PET raw data from 
each bed were reconstructed and collated together offline using the 
Siemens proprietary e7tools with an ordered subset expectation 
maximization (OSEM) algorithm with point spread function (PSF) 
correction. A dual-compartment (soft tissue and air) attenuation 
map was used for attenuation.
Imaging-based analysis of the nanobiologics’ 
biodistribution in nonhuman primates
Image analysis was performed using Osirix MD, version 11.0. 
Whole-body MR images were fused with PET images and analyzed 
in a coronal plane. Regions of interest (ROIs) were drawn on various 
tissues. The spleen, liver, kidneys, lungs, heart, cerebellum, and ce-
rebrum were traced in their entirety, and bone marrow uptake was 
assessed using three vertebrae in the lumbar spine. Mean standard-
ized uptake values (SUVs) were calculated for each ROI. Subse-
quently, 89Zr-labeled mTORi-NB uptake of each organ was expressed 
as the average of all mean SUV values per organ.
Blood chemistry
Nonhuman primate and mouse serum were collected, and blood 
chemistry analysis was performed by IDEXX BioAnalytics.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/10/eabe7853/DC1
View/request a protocol for this paper from Bio-protocol.
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